drugset
drugset / Trial / NCT07349225

Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy and Sequential Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer

NCT07349225 ↗

Phase 2 Not yet recruiting 46 enrolled The Second Affiliated Hospital of Dalian Medical University
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the efficacy and safety of Iparomlimab and Tuvonralimab Injection in combination with Chemotherapy and Sequential Thoracic Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer.

Timeline

Start
2026-01-31
Primary completion
2027-12-31
Completion
2028-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Iparomlimab Monoclonal antibody 5 mg/kg —
Subject Tuvonralimab Monoclonal antibody 5 mg/kg —
Background Cisplatin Other / unclassified 25 mg/m2 —
Background Etoposide Small molecule 100 mg/m2 —

Indications

small cell lung carcinoma